NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-052-2002-0-US-04 COMPOSITIONS AND METHODS FOR INHIBITING CELL GROWTH AND MODULATING GENE EXPRESSION US DIV 11/497,627 Abandoned
NIDDK E-165-1999-0-US-04 Potentiation of Antineoplastic Agents Using Sigma-2 Ligands US CON 11/497,945 Abandoned
NINDS E-261-2004-0-US-03 Peptidic Compound Mixtures As Therapeutic Agents In CNS Autoimmunity US National Stage 10/587,987 Abandoned
NCI E-035-1994-2-JP-17 ISOLATION OF CELLULAR MATERIAL UNDER MICROSCOPIC VISUALIZATION JP DIV 2006-208752 Abandoned
NIEHS E-103-2000-3-US-01 Biologically Potent Analogues of the DMT-TIC Pharmacophore and Methods of Use US 60/834,438 Abandoned
NCI E-211-2005-0-EP-05 Use Of Chk2 Kinase Inhibitors For Cancer Treatment EP National Stage 06800452.2 Abandoned
NCI E-211-2005-0-FR-08 Use Of Chk2 Kinase Inhibitors For Cancer Treatment FR EP 06800452.2 Abandoned
NCI E-211-2005-0-DE-07 Use Of Chk2 Kinase Inhibitors For Cancer Treatment DE EP 06800452.2 Abandoned
NCI E-211-2005-0-GB-09 Use Of Chk2 Kinase Inhibitors For Cancer Treatment GB EP 06800452.2 Abandoned
NCI E-211-2005-0-AU-03 Use Of Chk2 Kinase Inhibitors For Cancer Treatment AU National Stage 2006275679 Abandoned
NIDDK E-167-2005-0-PCT-02 Detecting and Characterizing Macromolecular Interactions in a Solution with a Simultaneous Measurement of Light Scattering and Concentration PCT PCT PCT/US2006/029413 Abandoned
NCI E-211-2005-0-PCT-02 Use Of Chk2 Kinase Inhibitors For Cancer Treatment PCT PCT PCT/US2006/029401 Expired
NCI E-078-2006-0-US-01 CKAP4/p63 Is A Bladder Epithelial Cell Bladder Cell Receptor For The Antiproliferative Factor (APF) From Interstitial Cystitis Patients US 60/833,828 Abandoned
NCI E-262-2005-0-EP-28 Mutated Pseudomonas Exotoxins with Reduced Antigenicity EP DIV 15191388.6 Issued
NCI E-262-2005-0-EP-30 Mutated Pseudomonas Exotoxins with Reduced Antigenicity EP DIV 15191395.1 Issued
NCI E-262-2005-0-EP-29 Mutated Pseudomonas Exotoxins with Reduced Antigenicity EP DIV 15191391.0 Issued
NCI E-262-2005-0-EP-08 Mutated Pseudomonas Exotoxins with Reduced Antigenicity EP DIV 10179539.1 Issued
NCI E-262-2005-0-GB-26 Mutated Pseudomonas Exotoxins with Reduced Antigenicity GB EP 10179539.1 Issued
NCI E-262-2005-0-ES-24 Mutated Pseudomonas Exotoxins with Reduced Antigenicity ES EP 10179539.1 Issued
NCI E-262-2005-0-FR-25 Mutated Pseudomonas Exotoxins with Reduced Antigenicity FR EP 10179539.1 Issued
NCI E-262-2005-0-DE-23 Mutated Pseudomonas Exotoxins with Reduced Antigenicity DE EP 10179539.1 Issued
NCI E-262-2005-0-IT-27 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IT EP 10179539.1 Issued
NCI E-262-2005-0-US-06 MUTATED PSEUDOMONAS EXOTOXINS WITH REDUCED ANTIGENICITY US National Stage 11/997,202 8907060 Issued PDF
NCI E-262-2005-0-EP-07 Mutated Pseudomonas Exotoxins with Reduced Antigenicity EP DIV 10179520.1 Issued
NCI E-262-2005-0-IT-21 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IT EP 10179520.1 Issued
NCI E-262-2005-0-ES-18 Mutated Pseudomonas Exotoxins with Reduced Antigenicity ES EP 10179520.1 Issued
NCI E-262-2005-0-DE-17 Mutated Pseudomonas Exotoxins with Reduced Antigenicity DE EP 10179520.1 Issued
NCI E-262-2005-0-FR-19 Mutated Pseudomonas Exotoxins with Reduced Antigenicity FR EP 10179520.1 Issued
NCI E-262-2005-0-GB-20 Mutated Pseudomonas Exotoxins with Reduced Antigenicity GB EP 10179520.1 Issued
NCI E-262-2005-0-CH-16 Mutated Pseudomonas Exotoxins with Reduced Antigenicity CH EP 10179520.1 Issued
NCI E-262-2005-0-AU-03 Mutated Pseudomonas Exotoxins with Reduced Antigenicity AU National Stage 2006275865 Issued
NCI E-108-2004-1-US-01 Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas US CIP 11/493,387 8131475 Issued PDF
NCI E-262-2005-0-EP-05 Mutated Pseudomonas Exotoxins with Reduced Antigenicity EP National Stage 06788523.6 Issued
NCI E-262-2005-0-GB-13 Mutated Pseudomonas Exotoxins with Reduced Antigenicity GB EP 06788523.6 Issued
NCI E-262-2005-0-CH-09 Mutated Pseudomonas Exotoxins with Reduced Antigenicity CH EP 06788523.6 Issued
NCI E-262-2005-0-IT-14 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IT EP 06788523.6 Issued
NCI E-262-2005-0-FR-12 Mutated Pseudomonas Exotoxins with Reduced Antigenicity FR EP 06788523.6 Issued
NCI E-262-2005-0-DE-10 Mutated Pseudomonas Exotoxins with Reduced Antigenicity DE EP 06788523.6 Issued
NCI E-262-2005-0-ES-11 Mutated Pseudomonas Exotoxins with Reduced Antigenicity ES EP 06788523.6 Issued
NCI E-180-2000-0-US-05 Specific Binding Agents for KSHV vIL-6 That Neutralize a Biological Activity US DIV 11/493,687 7235365 Abandoned PDF
NCI E-189-2006-0-PCT-01 Method For The Direct Detection and Quantitation Of Asparagine Synthetase In Biological Samples PCT PCT PCT/US2006/028965 Expired
NCI E-262-2005-0-PCT-02 Mutated Pseudomonas Exotoxins with Reduced Antigenicity PCT PCT PCT/US2006/028986 Expired
NCI E-132-2006-1-US-01 Materials and Methods Directed to Asparagine Synthetase and Asparaginase Therapies US 60/833,027 Abandoned
NICHD E-183-2005-0-US-01 New Methods For Conjugation Of Bacterial Lipoligosaccharides To Protein Carriers Through Oxime And Hydrazone Linkages US 60/832,448 Abandoned
NIAMS E-042-2005-0-PCT-02 Mechanoactive Microfluidic Imaging Bioreactor PCT PCT PCT/US2006/028417 Expired
NIAID E-280-2006-0-US-01 CRYSTAL STRUCTURE AND ITS USE US 60/832,458 Abandoned
ORS E-218-2003-0-US-03 Method And Apparatus For Bioweapon Decontamination US National Stage 10/597,191 7776292 Abandoned PDF
NCI E-263-2006-0-US-01 A Novel Algorithm For The Molecular Diagnosis Of Lymph Node Metasis And Prognosis In Early-stage Lung Adenocarcinoma By Profiling The Expression Of Unique Cytokines In Tumor And Non-tumor Specimens US 60/830,936 Abandoned
NCI E-237-2006-0-US-01 Use Of ABCB1 Genotyping To Predict Peripheral Neuropathy And Neutropenia Following Paclitaxel Treatment In Human Cancer US 60/807,453 Abandoned
NICHD E-282-2003-0-US-03 METHOD EVOLVED FOR RECOGNITION OF THROMBOPHILIA (MERT) US National Stage 10/586,288 Abandoned